Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

The Motley Fool

12 Jul 2026, 19:30 UTC · 2h ago

Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance?

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

What the story claims

4 claims · each scored for market impact

What matters in this story

1
The First Trust Biotechnology Fund (FBT) utilizes a highly concentrated portfolio of only 30 stocks, increasing its idiosyncratic risk compared to broader benchmarks. — Higher concentration in a volatile sector like biotech increases the risk of significant price swings based on a few individual company failures.
-0.30
2
The iShares Biotechnology ETF (IBB) provides broad diversification with 248 holdings and is heavily influenced by large-cap established players like Vertex, Amgen, and Gilead. — Market-cap weighting in established firms generally reduces volatility and provides more stability than concentrated small-cap bets.
+0.20
3
The iShares fund (IBB) has a lower expense ratio of 0.44% compared to 0.55% for the First Trust fund (FBT). — Lower fees marginally improve long-term net returns for investors, though the difference is relatively small.
+0.10
4